Fact File: The truth about penicillin allergy
19 out of 20 patients who think they are allergic to penicillin are wrong and are costing 63% more
The truth about penicillin allergy
It is has been reported that of the 30 million U.S. patients reporting to be penicillin allergic, 28.5 million actually are not. That means up to 19 out of 20 patients who think they are allergic to penicillin are misinformed. Antibiotic costs for patients who report penicillin allergies are as much as 63% higher.
- Penicillin is an antibiotic in the beta lactam family.
- 10% of patients report adverse reactions to penicillin including rash, allergic reaction and anaphylaxis.
- Many patients reporting allergies may not be allergic or their allergy may resolve over time.
- 80% of patients with a penicillin allergy will no longer be allergic 10 years after their initial reaction if they are not exposed again during this time period.
- About 90% of patients will test negative to a skin test, indicating they are not allergic to penicillin or that their previous allergy has resolved itself, however, skin testing is not 100% accurate.
Sources:
American Academy of Allergy Asthma and Immunology
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
